Literature DB >> 15956053

Centrally administered adrenomedullin 2 activates hypothalamic oxytocin-secreting neurons, causing elevated plasma oxytocin level in rats.

Hirofumi Hashimoto1, Susumu Hyodo, Makoto Kawasaki, Takashi Mera, Lei Chen, Atsushi Soya, Takeshi Saito, Hiroaki Fujihara, Takashi Higuchi, Yoshio Takei, Yoichi Ueta.   

Abstract

We examined the effects of intracerebroventricular (i.c.v.) administration of adrenomedullin 2 (AM2) on plasma oxytocin (OXT) and arginine vasopressin (AVP) levels in conscious rats. Plasma OXT levels were markedly increased 5 min after i.c.v. administration of AM2 (1 nmol/rat) compared with vehicle and remained elevated in samples taken at 10, 15, 30, and 60 min. By contrast, plasma AVP levels were not significantly elevated in samples taken between 5 and 180 min after i.c.v. administration of AM2 except at the 30-min time point. Fos-like immunoreactivity (Fos-LI) was observed in various brain areas, including the paraventricular (PVN) and the supraoptic nuclei (SON) after i.c.v. administration of AM2 (2 nmol/rat) in conscious rats (measured at 90 min post-AM2 infusion). Dual immunostaining for OXT/Fos and AVP/Fos showed that OXT-LI neurons predominantly exhibited nuclear Fos-LI compared with AVP-LI neurons in the PVN and the SON. In situ hybridization histochemistry showed that i.c.v. administration of AM2 (0.2, 1, and 2 nmol/rat) caused marked induction of the expression of the c-fos gene in the PVN and the SON. This induction was significantly reduced by pretreatment with both the calcitonin gene-related peptide (CGRP) antagonist CGRP-(8-37) (3 nmol/rat) and the AM receptor antagonist AM-(22-52) (27 nmol/rat). These results suggest that centrally administered AM2 mainly activates OXT-secreting neurons in the PVN and the SON, at least in part through the CGRP and/or AM receptors with marked elevation of plasma OXT levels in conscious rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956053     DOI: 10.1152/ajpendo.00042.2005

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  6 in total

1.  Possible involvement of central oxytocin in cisplatin-induced anorexia in rats.

Authors:  Koichi Arase; Hirofumi Hashimoto; Satomi Sonoda; Hiromichi Ueno; Reiko Saito; Yasuhito Motojima; Mitsuhiro Yoshimura; Takashi Maruyama; Keiji Hirata; Yasuhito Uezono; Yoichi Ueta
Journal:  J Physiol Sci       Date:  2017-06-14       Impact factor: 2.781

Review 2.  Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis.

Authors:  Kazuhiro Takahashi; Ryo Morimoto; Takuo Hirose; Fumitoshi Satoh; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2010-07-02       Impact factor: 3.444

Review 3.  The pharmacology of adrenomedullin 2/intermedin.

Authors:  Yanguo Hong; Debbie L Hay; Remi Quirion; David R Poyner
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  Oxytocin as a potential pharmacological tool to combat obesity.

Authors:  Pawel K Olszewski; Emily E Noble; Luis Paiva; Yoichi Ueta; James E Blevins
Journal:  J Neuroendocrinol       Date:  2022-02-22       Impact factor: 3.870

Review 5.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 6.  The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis.

Authors:  Elizabeth A Lawson; Pawel K Olszewski; Aron Weller; James E Blevins
Journal:  J Neuroendocrinol       Date:  2019-11-28       Impact factor: 3.627

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.